Related Experiment Videos
Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia
1Maudsley Hospital, Denmark Hill, London SE5 8AZ, UK.
Journal of Psychopharmacology (Oxford, England)
|September 22, 2005
Summary
The optimal dose for oral risperidone in schizophrenia relapse is around 4 mg daily. Higher doses do not improve efficacy and may increase adverse effects, including movement disorders.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Neuroscience
Background:
- Dose-response relationships for many antipsychotics are not well understood.
- High-dose antipsychotic treatment is frequently prescribed.
- Understanding optimal dosing is crucial for effective schizophrenia management.
Purpose of the Study:
- To determine the dose-response relationship for oral risperidone in patients with relapsed schizophrenia.
- To identify the optimal effective and safe dosage of risperidone.
Main Methods:
- Systematic literature search for fixed-dose studies of oral risperidone in relapsed schizophrenia.
- Data extraction and graphical analysis of dose versus treatment response.
- Inclusion of data from three relevant eight-week studies.
Main Results:
- Oral risperidone doses around 4 mg daily appear optimal for efficacy in relapsed schizophrenia.
- Lower efficacy was observed at 2 mg daily.
- Doses of 6 mg or higher showed no additional benefit and potentially reduced efficacy at 10 mg and above.
- Extrapyramidal adverse effects increased with rising risperidone dosage.
Conclusions:
- The optimal daily dose of oral risperidone for patients with relapsed schizophrenia is approximately 4 mg.
- Increasing the dose beyond 4 mg is unlikely to enhance therapeutic benefits and may lead to decreased efficacy.
- Higher risperidone doses are associated with a greater incidence of adverse movement disorders.